Dr. Biswa Mohan Sahoo
@cutm.ac.in
Professor
School of Pharmacy and Life Sciences, Centurion University of Technology & Management, BBSR
Dr. Biswa Mohan Sahoo is working as a professor at the School of Pharmacy and Life Sciences, Jatni, Bhubaneswar, Odisha. Dr. Sahoo completed his M.Pharm from L.M College of Pharmacy, Gujrat University, Ahmedabad, and PhD from the School of Pharmaceutical Education and Research, Berhampur University, Odisha. He has also completed his postgraduate diploma in Pharmaceutical Regulatory Affairs from Hamdard University, New Delhi. He has published several research and review articles in peer-reviewed journals of national and international repute. He has authored several textbooks of international repute. He has published 8 patents in India and Australia. Dr Sahoo is a recipient of the University Foundation Research Award-2019, 2022, and Startup Cell Award-2022, organized by BPUT, Rourkela, Odisha, Young Scientist Award by Indian Pharma Educational Society (IPES), Health Care Award-2018 by Venous International Foundation, Scientific Excellence Award-2018 by Marina Laboratory.
EDUCATION
B. Pharm. Degree in the year 2005 from Berhampur University, Berhampur, Odisha, India.
Master degree from Department of Medicinal Chemistry, L.M College of Pharmacy, Gujarat, India.
Doctor of Pharmacy from School of Pharmaceutical Education and Research (SPER), Berhampur University, India in 2013.
RESEARCH, TEACHING, or OTHER INTERESTS
Pharmaceutical Science, Drug Discovery, Chemistry, Pharmacology, Toxicology and Pharmaceutics
Scopus Publications
Scholar Citations
Scholar h-index
Scholar i10-index
Scopus Publications
Biswa Mohan Sahoo, Pooja Chawla, Subas Chandra Dinda, Narahari Narayan Palei, Bhupendra Singh, and Bibhas Chandra Mohanta
De Gruyter
Narahari Narayan Palei, Abhishek Singh, Seema Yadav, and Biswa Mohan Sahoo
De Gruyter
Narahari Narayan Palei, Abhishek Singh, Seema Yadav, and Biswa Mohan Sahoo
De Gruyter
Bimal Krishna Banik and Biswa Mohan Sahoo
Elsevier
Abhishek Tiwari, Varsha Tiwari, Bimal Krishna Banik, and Biswa Mohan Sahoo
Elsevier
Adya Jain, Biswa Mohan Sahoo, and Bimal Krishna Banik
Elsevier
Biswa Mohan Sahoo and Bimal Krishna Banik
Elsevier
Bimal Krishna Banik and Biswa Mohan Sahoo
Elsevier
Bimal Krishna Banik, Biswa Mohan Sahoo, Binayani Sahoo, and Bibhash C. Mohanta
Elsevier
Monika Meghani, Shikha Sharma, Nitin Kumar, and Biswa Mohan Sahoo
Bentham Science Publishers Ltd.
Background: The severe acute respiratory illness that was brought on because of the outbreak of COVID-19 caused by the SARS-CoV-2 infection has been designated as a public health emergency of worldwide concern. There is an immediate and pressing need to establish an effective therapeutic strategy to bring infections under control. COVID-19 viral spike glycoproteins and proteases both play important roles in the process of viral entrance as well as in the process of virus reproduction. Methods: Benzimidazole derivatives show antiviral activity against various RNA and DNA viruses and stop the early viral replication cycle. Based on this information, we designed eighteen new benzimidazole derivatives and screened them against the proteins S-glycoprotein 6VSB and papain-like protease 6W9C using molecular docking studies. Compounds that bind strongly to these proteins were evaluated again in an in vitro study. Results: When docked with SARS-CoV-2 spike glycoprotein, the binding affinity of R1 and R7 was –7.1 kcal/mol and -7.3 kcal/mol, respectively. This showed that they might be able to stop the SARS spike protein from binding to the ACE2 receptor on the human host, making it harder for the virus to get into the cells. The binding affinity of SARS-CoV-2 papain-like protease with R4, R14, and R15 was –6.7 kcal/mol, -6.5 kcal/mol, and –6.5 kcal/mol, respectively. COVID-19 could stop the protease from working by binding it. Conclusion: It was suggested, on the basis of the binding energy score, that these pharmacologically potent benzimidazole derivatives may be tested against SARS-CoV-2 and utilized in the production of efficient antiviral medicines
Adya Jain, Biswa Mohan Sahoo, and Bimal Krishna Banik
Elsevier
Varsha Tiwari, Abhishek Tiwari, Bimal Krishna Banik, and Biswa Mohan Sahoo
Elsevier
Biswa Mohan Sahoo, Bimal Krishna Banik, Preetismita Borah, Adya Jain, Abhishek Tiwari, and Manoj Kumar Mahapatra
Elsevier
Biswa Mohan Sahoo, Dipthi Shree, Bimal Krishna Banik, Preetismita Borah, Adya Jain, and Manoj Kumar Mahapatra
Elsevier
Biswa Mohan Sahoo, Bimal Krishna Banik, Arun Kumar Mahato, and C. Nithya Shanthi
Elsevier
Jnyanaranjan Panda, Biswa Mohan Sahoo, and Bimal Krishna Banik
Elsevier
Biswa Mohan Sahoo and Bimal Krishna Banik
Elsevier
Varsha Tiwari, Abhishek Tiwari, Bimal Krishna Banik, and Biswa Mohan Sahoo
Elsevier
Bimalendu Chowdhury, Biswa Mohan Sahoo, Akankshya Priyadarsani Jena, Korikana Hiramani, Amulyaratna Behera, and Biswajeet Acharya
Bentham Science Publishers Ltd.
Abstract: COVID-19 is an RNA virus that attacks the targeting organs, which express angiotensin- converting enzyme-2 (ACE-2), such as the lungs, heart, renal system, and gastrointestinal tract. The virus that enters the cell by endocytosis triggers ROS production within the confines of endosomes via a NOX-2 containing NADPH-oxidase. Various isoforms of NADPH oxidase are expressed in airways and alveolar epithelial cells, endothelial and vascular smooth muscle cells, and inflammatory cells, such as alveolar macrophages, monocytes, neutrophils, and Tlymphocytes. The key NOX isoform expressed in macrophages and neutrophils is the NOX-2 oxidase, whereas, in airways and alveolar epithelial cells, it appears to be NOX-1 and NOX-2. The respiratory RNA viruses induce NOX-2-mediated ROS production in the endosomes of alveolar macrophages. The mitochondrial and NADPH oxidase (NOX) generated ROS can enhance TGF-β signaling to promote fibrosis of the lungs. The endothelium-derived ROS and platelet-derived ROS, due to activation of the NADPH-oxidase enzyme, play a crucial role in platelet activation. It has been observed that NOX-2 is generally activated in COVID-19 patients. The post-COVID complications like pulmonary fibrosis and platelet aggregation may be due to the activation of NOX-2. NOX-2 inhibitors may be a useful drug candidate to prevent COVID-19 complications like pulmonary fibrosis and platelet aggregation.
Pallepogu Venkateswara Rao, Naidu Srinivasa Rao, Biswa Mohan Sahoo, and Nayaka Raghavendra Babu
Bentham Science Publishers Ltd.
Background: The reverse-phase high-performance liquid chromatography (RP-HPLC) method was developed for the quantitative measurement of monoclonal antibodies (Maftivimab, Atoltivimab, and Odesivimab) in the pharmaceutical dosage form. The Food and Drug Administration (FDA) has approved these monoclonal antibodies for the treatment of Zaire ebolavirus infection in adults Methods: Maftivimab, Atoltivimab, and Odesivimab were separated chromatographically on the Waters Alliance-e2695 platform using the Luna Phenyl Hexyl (250 x 4.6 mm, 5 μm) column and a mobile phase made up of Acetonitrile (ACN) and ortho-phosphoric acid (OPA) buffer in a ratio of 70:30 (v/v). Results: The flow rate was 1.0 ml/min, and a photodiode array (PDA) detector operating at room temperature was used to measure absorption at 282 nm. For Maftivimab, Atoltivimab, and Odesivimab, the theoretical plates were not less than 2000, and the tailing factor shouldn't be greater than 2, accordingly. All measurements have a constant relative standard deviation of peak areas that is less than 2.0. Conclusion: The suggested procedure was approved following the International Conference on Harmonisation (ICH) recommendations. When used for the quantitative analysis of Maftivimab, Atoltivimab, and Odesivimab, the approach was found to be straightforward, affordable, appropriate, exact, accurate, and robust.
Dipthi Shree, Chinam Niranjan Patra, and Biswa Mohan Sahoo
Bentham Science Publishers Ltd.
Abstract: In recent years, herbal nanomedicines have gained tremendous popularity for novel drug discovery. Nanotechnology has provided several advances in the healthcare sector, emerging several novel nanocarriers that potentiate the bioavailability and therapeutic efficacy of the herbal drug. The recent advances in nanotechnology with accelerated strategies of ophthalmic nanosystems have paved a new path for overcoming the limitations associated with ocular drug delivery systems, such as low bioavailability, poor absorption, stability, and precorneal drug loss. Ophthalmic drug delivery is challenging due to anatomical and physiological barriers. Due to the presence of these barriers, the herbal drug entry into the eyes can be affected when administered by following multiple routes, i.e., topical, injectables, or systemic. However, the advancement of nanotechnology with intelligent systems enables the herbal active constituent to successfully entrap within the system, which is usually difficult to reach employing conventional herbal formulations. Herbal-loaded nanocarrier drug delivery systems demonstrated enhanced herbal drug permeation and prolonged herbal drug delivery. : In this current manuscript, an extensive search is conducted for original research papers using databases Viz., PubMed, Google Scholar, Science Direct, Web of Science, etc. Further painstaking efforts are made to compile and update the novel herbal nanocarriers such as liposomes, polymeric nanoparticles, solid lipid nanoparticles, nanostructure lipid carriers, micelles, niosomes, nanoemulsions, dendrimers, etc., which are mostly used for ophthalmic drug delivery system. This article presents a comprehensive survey of diverse applications used for the preventative measures and treatment therapy of varied eye disorders. Further, this article highlights the recent findings that the innovators are exclusively working on ophthalmic nanosystems for herbal drug delivery systems. : The nanocarriers are promising drug delivery systems that enable an effective and supreme therapeutic potential circumventing the limitations associated with conventional ocular drug delivery systems. The nanotechnology-based approach is useful to encapsulate the herbal bioactive and prevent them from degradation and therefore providing them for controlled and sustained release with enhanced herbal drug permeation. Extensive research is still being carried out in the field of herbal nanotechnology to design an ophthalmic nanosystem with improved biopharmaceutical properties.
Biswa Mohan Sahoo, Pallepogu Venkateswara Rao, and Naidu Srinivasa Rao
Bentham Science Publishers Ltd.
Background: A novel, simple, efficient, rapid, and precise reverse-phase highperformance liquid chromatography (RP-HPLC) method was developed for the estimation of Tenofovir and Emtricitabine in the bulk and pharmaceutical dosage form. The currently developed method was subsequently validated according to ICH guidelines in terms of linearity, accuracy, precision, the limit of detection, the limit of quantification, robustness, etc. Methods: The separation of the selected drugs was optimized after several trials including change of mobile phase and its composition, stationary phase, flow rate, column temperature, etc. The separation was performed by using an Inertsil ODS C18 column (250 mm x 4.6 mm, 5μ) and UV absorption was measured at 231 nm. Methanol: Acetonitrile: Water was selected as the mobile phase in the ratio of 50:20:30 (V/V/V) at a flow rate of 1 mL/min. As per International Conference on Harmonization (ICH) Q2 R1 guidelines, several validation parameters were evaluated which include specificity, linearity, precision, accuracy, the limit of detection (LOD), and the limit of quantitation (LOQ). Results: The acceptable degree of linearity range was found to be 40-100 μg/mL. The standard solution exhibited retention times of 3.06 minutes and 5.07 minutes for Tenofovir and Emtricitabine respectively. The LOD and LOQ obtained were 0.05 μg/ml and 0.02 μg/mL, 15 μg/mL, and 0.08 μg/mL for Tenofovir and Emtricitabine respectively. The percent recovery was found to be 98 to 102%. Conclusion: Hence, the proposed method is simple, selective, and specifically meets the requirements of ICH guidelines for the validation of the analytical method.
Dipthi Shree, Chinam Niranjan Patra, and Biswa Mohan Sahoo
Bentham Science Publishers Ltd.
Abstract: Since ancient times, traditional herbs have been widely used around the world for health promotion and therapy. Obesity is a complex metabolic disorder and is becoming a mammoth problem that adversely affects an individual’s quality of life. Conventional therapy for the management of obesity mainly involves the use of synthetic moiety and bariatric surgical procedures which has severe side effects and patient non-compliance. To circumvent these limitations, plant-derived medicines are utilized which are safe, effective, economic, and easily available. The advancement of nanotechnology enables the development of novel strategies that could potentiate the therapeutic efficacy of the phytoconstituents with minimal toxic effects and promotes the controlled release of the plant bioactive compounds. Moreover, great efforts have been made through targeted nanotechnology-based herbal treatment, where novel nanocarriers are employed as herbal drug delivery vehicles to improve the pharmacokinetics of antiobesity drugs. The recent advancement in phytonanotechnology have opened an avenue to explore novel carriers to utilize bioactive compounds in biomedical and therapeutic applications. In the current review, an extensive search is conducted for the existing original research articles using databases i.e., Google Scholar, PubMed, ScienceDirect, Embase, Baidu, etc. Further, painstaking efforts are made to compile and update the novel herbal nanocarriers such as liposomes, solid lipid nanoparticles, etc. which are widely used for the treatment of obesity. This article portrays a comprehensive survey of the novel strategies employed by the innovators working exclusively on herbal drug delivery systems. The recent development of nanotechnology-based herbal drug delivery has a wide range of biomedical applications and has provided an unprecedented opportunity to improve the treatment of obesity and obesity-related comorbidities. Furthermore, the advancement of phytopharmacological science has led to several novel strategies with improved nanotherapeutics for the management of obesity. Scientific research is still being carried out in the field of nanotechnology for a better perspective on herbal drug delivery for obesity treatment over conventional therapy.
Biswa Mohan Sahoo, Bimal Krishna Banik, Abhishek Tiwari, Varsha Tiwari, Adya Jain, and Preetismita Borah
Walter de Gruyter GmbH
Abstract Organotellurium compounds define the compounds containing carbon (organic group) and tellurium bond (C–Te). The first organic compound containing tellurium was prepared by Wohler in 1840 after the discovery of the metal by the Austrian chemist F. J. Muller von Reichenstein in the year 1782. The term tellurium was derived from Latin tellus. Tellurium was observed first time in ores mined in the gold districts of Transylvania. Naturally occurring tellurium compounds are present in various forms based on their oxidation states such as TeO2 (+4) and TeO3 (+6). These oxidation states of tellurium compounds are more stable as compared to the other oxidation states. Tellurium is a rare element and is considered a non-essential, toxic element. Tellurium possesses only one crystalline form which consists of a network of spiral chains similar to that of hexagonal selenium. Tellurium is used for the treatment and prevention of microbial infections prior to the development of antibiotics. Hence, the utilization of organotellurium compounds plays a significant role as reagents and intermediates in various organic syntheses.
N. Raghavendra Babu, B. M. Sahoo, T. Radhika, B. Kumar C, and N. Malothu
Pleiades Publishing Ltd